Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

National Cancer Institute

Headquarters: Bethesda, MD, United States of America
Year Founded: 1937
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Jan 18, 2025
Management Tracks

Moves at FDA, NIH

Plus: updates on AZ, Actimed, Kailera, Nasus and more
BioCentury | Nov 23, 2024
Finance

ATB’s €54M series A among largest ever in Belgium

BioCentury’s Financial Report also includes new biotech foundry Jupiter, and public equity fundings for Spyre, Cidara and Aclaris
BioCentury | Nov 14, 2024
Management Tracks

New CEOs at Valo, Apriori

Plus: Glasspool to lead VarmX, Novartis vet Eissa joins Cellares and updates from Mestag, Andera, Incyclix and more
BioCentury | Jul 31, 2024
Regulation

ODAC calls for major change to perioperative checkpoint inhibitor studies

An FDA advisory committee wants more arms in trials to separately gauge checkpoint inhibitor efficacy before and after surgery
BioCentury | May 14, 2024
Politics, Policy & Law

Bolstering the U.S. bioeconomy: a Q&A with Rep. Auchincloss

Massachusetts lawmaker seeks to shape life sciences policy
BioCentury | Apr 25, 2024
Product Development

Building bridges between biomedical stakeholders: guiding principle for new NCI director

A Q&A with W. Kimryn Rathmell as she takes the reins at NCI
BioCentury | Jan 31, 2024
Distillery Therapeutics

Optimized B7-H3 ADC with PBD payload for solid tumors

BioCentury | Dec 7, 2023
Discovery & Translation

Zhang team discovers new CRISPR-Cas systems; plus E3 ligase targets and more

BioCentury’s roundup of translational innovations
Items per page:
1 - 10 of 1424